Tryg A/S
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme
Tryg - Transactions in connection with share buyback programme
On 04 December 2024, Tryg A/S (“Tryg”) announced that the Board of Directors had decided to initiate a share buyback programme of up to DKK 2.0 billion. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 30 June 2025.
Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.
The following transactions have been executed in the period 24 March 2025 to 28 March 2025:
| | Number of shares | Avg. purchase price, DKK | Transaction value, DKK |
| 24 March 2025 | 60,000 | 161.64 | 9,698,400 |
| 25 March 2025 | 70,000 | 162.20 | 11,354,000 |
| 26 March 2025 | 65,000 | 162.64 | 10,571,600 |
| 27 March 2025 | 65,000 | 164.74 | 10,708,100 |
| 28 March 2025 | 65,000 | 165.51 | 10,758,150 |
| Accumulated for the period | 325,000 | | 53,090,250 |
| Accumulated under the programme | 8,760,787 | | 1,337,401,154 |
Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.
Following the above transactions, Tryg owns a total of 9,262,283 treasury shares corresponding to 1.503% of the total share capital.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ProvaDent2.4.2025 03:18:11 CEST | Press release
ProvaDent Reviews (DENTIST INVESTIGATED): Can This Oral Probiotic Really Strengthen Teeth and Reverse Years of Damage?
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
nCino, Inc.1.4.2025 22:06:00 CEST | Press release
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom